HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
IND 179135 Research
Phase 1 mab active
Quick answer
HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use for HIV Infections is a Phase 1 program (mab) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lxo Ireland Designated Activity Company
- Indication
- HIV Infections
- Phase
- Phase 1
- Modality
- mab
- Status
- active